• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

九种新型大环内酯类药物的体外效价比较

Comparative in vitro potencies of nine new macrolides.

作者信息

Fernandes P B, Hardy D J

机构信息

Anti-infective Research, Abbott Laboratories, Abbott Park, IL 60064.

出版信息

Drugs Exp Clin Res. 1988;14(7):445-51.

PMID:3240705
Abstract

The in vitro activities of the 14-membered macrolides (14M) clarithromycin (CL), roxithromycin (RO), dirithromycin (DI) and flurithromycin (FL), a 15-membered macrolide (15M) azithromycin (AZ), and the 16-membered macrolides (16M) josamycin (JM), spiramycin (SP), miocamycin (MI) and rokitamycin (RK) were compared with erythromycin (ER). CL was two- to four-fold more potent than ER against all organisms except Haemophilus and Campylobacter jejuni against which it was two-fold less active. RO and DI were generally two- to four-fold less active than ER. FL was two-fold less active than ER. AZ was equal to or two-fold less active than ER against Gram-positive bacteria and two- to four-fold more active than ER against Gram-negative bacteria, such as Haemophilus, Neisseria gonorrhoeae and Branhamella. The 16M were generally four- to eight-fold less active than ER against most aerobic bacteria and two-fold less active than ER against anaerobic bacteria. RK was generally two-fold more active than the other 16M. Bacteria carrying a constitutive-type of MLS resistance were resistant to the 14M, 15M and 16M, whereas bacteria with an inducible-type of resistance were susceptible to the 16M but resistant to the 14M and 15M. Addition of serum to the medium increased the activity of ER, CL, DI, FL, AZ and SP. The activity of RO was reduced four- to six-fold and the activity of MI was reduced by two-fold by adding serum to the medium. The activity of JO was unaffected by serum. All the macrolides were one- to four-fold more active at pH 8.0 than at pH 6.5. All the macrolides were bacteriostatic against Staphylococcus aureus 553, except RO and MI which were slowly bactericidal. All the macrolides were slowly bactericidal against Haemophilus influenzae 1435.

摘要

将14元大环内酯类药物(14M)克拉霉素(CL)、罗红霉素(RO)、地红霉素(DI)和氟红霉素(FL)、15元大环内酯类药物(15M)阿奇霉素(AZ)以及16元大环内酯类药物(16M)交沙霉素(JM)、螺旋霉素(SP)、米卡霉素(MI)和罗他霉素(RK)的体外活性与红霉素(ER)进行了比较。除流感嗜血杆菌和空肠弯曲菌外,CL对所有微生物的活性比ER高2至4倍,而对这两种菌的活性比ER低2倍。RO和DI的活性一般比ER低2至4倍。FL的活性比ER低2倍。AZ对革兰氏阳性菌的活性与ER相当或比ER低2倍,而对革兰氏阴性菌,如流感嗜血杆菌、淋病奈瑟菌和布兰汉菌的活性比ER高2至4倍。16M对大多数需氧菌的活性一般比ER低4至8倍,对厌氧菌的活性比ER低2倍。RK的活性一般比其他16M高2倍。携带组成型MLS耐药的细菌对14M、15M和16M耐药,而具有诱导型耐药的细菌对16M敏感,但对14M和15M耐药。向培养基中添加血清可增加ER、CL、DI、FL、AZ和SP的活性。向培养基中添加血清会使RO的活性降低4至6倍,使MI的活性降低2倍。JO的活性不受血清影响。所有大环内酯类药物在pH 8.0时的活性比在pH 6.5时高1至4倍。除RO和MI具有缓慢杀菌作用外,所有大环内酯类药物对金黄色葡萄球菌553均有抑菌作用。所有大环内酯类药物对流感嗜血杆菌1435均有缓慢杀菌作用。

相似文献

1
Comparative in vitro potencies of nine new macrolides.九种新型大环内酯类药物的体外效价比较
Drugs Exp Clin Res. 1988;14(7):445-51.
2
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.新型14元、15元及16元大环内酯类药物的体外活性比较
Antimicrob Agents Chemother. 1988 Nov;32(11):1710-9. doi: 10.1128/AAC.32.11.1710.
3
[Comparative in vitro bacteriostatic and bactericidal effect of 5 macrolides: roxithromycin, erythromycin, oleandomycin, josamycin and spiramycin against 284 hospital bacterial strains].5种大环内酯类药物:罗红霉素、红霉素、竹桃霉素、交沙霉素和螺旋霉素对284株医院分离菌株的体外抑菌和杀菌效果比较
Pathol Biol (Paris). 1989 Jun;37(5 Pt 2):553-9.
4
[In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes].新型半合成大环内酯类药物罗红霉素对专性厌氧菌的体外活性
Pathol Biol (Paris). 1986 May;34(5):440-4.
5
The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.一些14元、15元和16元大环内酯类药物对葡萄球菌属、军团菌属、支原体属和溶脲脲原体的体外活性。
Drugs Exp Clin Res. 1991;17(2):91-9.
6
Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.针对流感嗜血杆菌、卡他莫拉菌和肺炎链球菌近期临床分离株对地红霉素进行的体外比较评估,包括培养基补充成分和试验条件对最低抑菌浓度(MIC)结果的影响。
Diagn Microbiol Infect Dis. 1999 Apr;33(4):275-82.
7
[In vitro antibacterial activity of a new macrolide: miokamycin. Comparison with erythromycin and josamycin].一种新型大环内酯类抗生素:米卡霉素的体外抗菌活性。与红霉素和交沙霉素的比较
Pathol Biol (Paris). 1988 May;36(5):370-6.
8
The in-vitro activity of roxithromycin, a new macrolide antibiotic, in comparison with that of erythromycin.新型大环内酯类抗生素罗红霉素与红霉素的体外活性比较。
Drugs Exp Clin Res. 1987;13(9):563-6.
9
In-vitro activity of dirithromycin in comparison with other new and established macrolides.地红霉素与其他新型及已上市大环内酯类药物的体外活性比较。
J Antimicrob Chemother. 1993 Mar;31 Suppl C:39-49. doi: 10.1093/jac/31.suppl_c.39.
10
[In vitro antibacterial activity of rokitamycin, a new macrolide antibiotic. Results of a multicenter study].[新型大环内酯类抗生素罗他霉素的体外抗菌活性。一项多中心研究的结果]
Pathol Biol (Paris). 1990 May;38(5):407-12.

引用本文的文献

1
Azithromycin through the Lens of the COVID-19 Treatment.从新冠肺炎治疗视角看阿奇霉素
Antibiotics (Basel). 2022 Aug 5;11(8):1063. doi: 10.3390/antibiotics11081063.
2
The macrolide antibiotic renaissance.大环内酯类抗生素的复兴
Br J Pharmacol. 2017 Sep;174(18):2967-2983. doi: 10.1111/bph.13936. Epub 2017 Aug 10.
3
From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials.从红霉素到阿奇霉素和新的潜在核糖体结合型抗菌药物。
Antibiotics (Basel). 2016 Sep 1;5(3):29. doi: 10.3390/antibiotics5030029.
4
Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.克拉霉素和奥美拉唑作为幽门螺杆菌相关性胃部疾病患者的幽门螺杆菌根除疗法。
Drugs. 1996 Jan;51(1):161-78. doi: 10.2165/00003495-199651010-00010.
5
Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens.克拉霉素和阿奇霉素对呼吸道病原体的比较药效学
Infection. 1995 Sep-Oct;23(5):316-21. doi: 10.1007/BF01716300.
6
Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension.多剂量口服阿奇霉素混悬液后在儿科患者中的药代动力学
Antimicrob Agents Chemother. 1993 Feb;37(2):314-6. doi: 10.1128/AAC.37.2.314.
7
Clarithromycin clinical pharmacokinetics.克拉霉素的临床药代动力学。
Clin Pharmacokinet. 1993 Sep;25(3):189-204. doi: 10.2165/00003088-199325030-00003.
8
Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.地红霉素。对其抗菌活性、药代动力学特性及治疗效果的综述。
Drugs. 1994 Oct;48(4):599-616. doi: 10.2165/00003495-199448040-00008.
9
Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.米卡霉素。对其抗菌活性、药代动力学特性及治疗潜力的综述。
Drugs. 1993 Oct;46(4):720-45. doi: 10.2165/00003495-199346040-00008.
10
Levels of flurithromycin in female genital tissue.女性生殖组织中氟红霉素的含量。
Antimicrob Agents Chemother. 1995 Aug;39(8):1899-901. doi: 10.1128/AAC.39.8.1899.